Skip to Content
Merck
CN

H5166

Erythropoietin human

EPO, recombinant, expressed in HEK 293 cells, suitable for cell culture

Synonym(s):

EPO

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

CAS Number:
11096-26-7
UNSPSC Code:
12352202
NACRES:
NA.77
MDL number:
MFCD00131025

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Erythropoietin human, EPO, recombinant, expressed in HEK 293 cells, suitable for cell culture

biological source

human

recombinant

expressed in HEK 293 cells

assay

≥95% (SDS-PAGE)

form

lyophilized powder

potency

≤5.0 ng/mL ED50

quality

endotoxin tested

mol wt

dimer 36 kDa (glycosylated)

packaging

pkg of 10 μg

storage condition

avoid repeated freeze/thaw cycles

technique(s)

cell culture | mammalian: suitable

impurities

≤1 EU/μg

UniProt accession no.

P01588

storage temp.

−20°C

Quality Level

100

Gene Information

human ... EPO(2056)

Looking for similar products? Visit Product Comparison Guide

Analysis Note

The specific activity was determined by the dose-dependent stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line).

Biochem/physiol Actions

Erythropoietin (EPO), produced primarily by the kidney, is the primary regulatory factor of erythropoiesis. It promotes the proliferation, differentiation, and survival of the erythroid progenitors. Erythropoietin stimulates erythropoiesis by inducing growth and differentiation of burst forming units and colony forming units into mature red blood cells. EPO produced by kidney cells is increased in response to hypoxia or anemia. The biological effects of erythropoietin are mediated by the erythropoietin receptor, which binds EPO with high affinity and is a potent EPO antagonist.
Erythropoietin is a glycoprotein that is the principal regulator of red blood cell growth and differentiation.

General description

EPO has been cloned from various species including human, murine, canine, and others. The mature proteins from the various species are highly conserved and exhibit greater than 80% amino acid sequence identity. EPO contains three N-linked glycosylation sites. The glycosylation of erythropoietin is required for the biological activities of erythropoietin in vivo.

Preparation Note

Human EPO is expressed as a glycosylated 36 kDa monomer in human HEK 293 cells. Production in human HEK 293 cells offers authentic glycosylation. Glycosylation contributes to stability in cell growth media and other applications.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

胰岛素激素类产品
常规特殊物品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000100862
0000100862
029M4845V
MKCJ9962
MKCH5150

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

François Roubille et al.
Cardiovascular drugs and therapy, 27(4), 315-331 (2013-05-23)
Erythropoietin (EPO) is the main hormone that regulates erythropoiesis. Beyond its well-known hematopoietic action, EPO has diverse cellular effects in non-hematopoietic tissues. It has been shown to inhibit apoptosis by activating pro-survival pathways in the myocardium, to mobilize endothelial progenitor
H Franklin Bunn
Cold Spring Harbor perspectives in medicine, 3(3), a011619-a011619 (2013-03-05)
During the past century, few proteins have matched erythropoietin (Epo) in capturing the imagination of physiologists, molecular biologists, and, more recently, physicians and patients. Its appeal rests on its commanding role as the premier erythroid cytokine, the elegant mechanism underlying
Cynthia So-Osman et al.
Anesthesiology, 120(4), 839-851 (2014-01-16)
Patient blood management combines the use of several transfusion alternatives. Integrated use of erythropoietin, cell saver, and/or postoperative drain reinfusion devices on allogeneic erythrocyte use was evaluated using a restrictive transfusion threshold. In a factorial design, adult elective hip- and
Russia Ha-Vinh Leuchter et al.
JAMA, 312(8), 817-824 (2014-08-27)
Premature infants are at risk of developing encephalopathy of prematurity, which is associated with long-term neurodevelopmental delay. Erythropoietin was shown to be neuroprotective in experimental and retrospective clinical studies. To determine if there is an association between early high-dose recombinant
Rajasekhar N V S Suragani et al.
Nature medicine, 20(4), 408-414 (2014-03-25)
Erythropoietin (EPO) stimulates proliferation of early-stage erythrocyte precursors and is widely used for the treatment of chronic anemia. However, several types of EPO-resistant anemia are characterized by defects in late-stage erythropoiesis, which is EPO independent. Here we investigated regulation of
View All Related Papers

Articles

Validated Animal Component-Free Growth Factors for Cell Culture

Discover validated bioactivity and proliferation data for our portfolio of animal component-free cell culture growth factors.

Hematopoietic Cytokines

Read article on hematopoietic cytokines and hematopoiesis

Protocols

Induced Pluripotent Stem Cell Reprogramming Protocols

Stem cell reprogramming protocols to generate human induced pluripotent stem cells (iPSCs) including viral and non-viral RNA based methods.

诱导多能干细胞重编程实验方案

产生人诱导多能干细胞（iPSC）的干细胞重编程实验方案，包括基于病毒和非病毒RNA的方法。

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service